Sector
PharmaceuticalsOpen
₹2.1Prev. Close
₹2.2Turnover(Lac.)
₹0.01Day's High
₹2.1Day's Low
₹2.152 Week's High
₹052 Week's Low
₹0Book Value
₹-35.74Face Value
₹10Mkt Cap (₹ Cr.)
5.05P/E
0EPS
0Divi. Yield
0No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2012 | Mar-2011 | Mar-2010 |
|---|---|---|---|
Equity Capital | 24.04 | 24.04 | 24.04 |
Preference Capital | 0 | 0 | 0 |
Reserves | -83.21 | -66 | -1.69 |
Net Worth | -59.17 | -41.96 | 22.35 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2012 | Mar-2011 |
|---|---|---|
Revenue | 26.46 | 28.4 |
yoy growth (%) | -6.83 | |
Raw materials | -4.7 | -7.81 |
As % of sales | 17.76 | 27.51 |
Employee costs | -9.64 | -9.35 |
| Y/e 31 Mar( In .Cr) | Mar-2012 | Mar-2011 |
|---|---|---|
Profit before tax | -17.21 | -45.12 |
Depreciation | -9.13 | -22.34 |
Tax paid | 0 | -7.69 |
Working capital | -7.93 | |
Other operating items |
| Y/e 31 Mar | Mar-2012 | Mar-2011 |
|---|---|---|
Growth matrix (%) | ||
Revenue growth | -6.83 | |
Op profit growth | -87.36 | |
EBIT growth | -72.79 | |
Net profit growth | -73.23 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,819 | 158.19 | 4,36,103.12 | 863.29 | 0.74 | 5,123.67 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 5,782.35 | 83.58 | 1,53,540.39 | 518 | 0.52 | 2,302 | 513.62 |
Mankind Pharma Ltd MANKIND | 2,910.6 | 59.91 | 1,20,073.47 | 634.43 | 0 | 2,529.74 | 334.18 |
Cipla Ltd CIPLA | 1,475.75 | 28.16 | 1,19,195.76 | 1,178.16 | 0.88 | 3,969.86 | 360.73 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,399.45 | 70.36 | 1,15,106.89 | 460 | 0.82 | 2,376 | 222.38 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Managing Director
Nalin Bamzai
Director (Technical)
Rajesh Agrawal
Director
Sanjay Sinha
Director
Yogendra Kumar Chauhan
Company Secretary
Manish Bhojwani
Additional Director
Avantika Varma
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by KDL Biotech Ltd
Summary
Promoted by the Parijat Enterprises, Kopran is currently an integrated health care company. The company has used research-based technology to contribute towards total health-care. From diagnostics to treatment, speciality bulks to finished dosage forms, bio-technology to sophisticated and medical electronic equipments maintaining quality on par with the best in the world, and thereby vying for brand equity in the global context.The companys major foray into the business of biotechnology based products its name is changed from Kopran Drugs to KDL Biotech (KDL).The company started modestly as a Semi Synthetic Penicillin (SSP) player and expanded to becomes the largest SSP Player in India with an annual SSP facility of over 1200 TPA. Subsequently the SSP business was hived off into a separate Company in a joint venture with Synpac Pharmaceuticals Ltd, UK.Its is growing with a vision to focus on Brand Equity Development, Research for New Chemical Entities and globalise its operations thus making KDL a truly International Pharmaceutical Company.
Read More
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
